JP6433985B2 - 脳神経の耳麻酔により疾患を処置する方法 - Google Patents

脳神経の耳麻酔により疾患を処置する方法

Info

Publication number
JP6433985B2
JP6433985B2 JP2016512111A JP2016512111A JP6433985B2 JP 6433985 B2 JP6433985 B2 JP 6433985B2 JP 2016512111 A JP2016512111 A JP 2016512111A JP 2016512111 A JP2016512111 A JP 2016512111A JP 6433985 B2 JP6433985 B2 JP 6433985B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
subject
administration
nerve
tonsillectomy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016512111A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016522819A (ja
JP2016522819A5 (enExample
Inventor
エム．クルーズ トーマス
エム．クルーズ トーマス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2016522819A publication Critical patent/JP2016522819A/ja
Publication of JP2016522819A5 publication Critical patent/JP2016522819A5/ja
Application granted granted Critical
Publication of JP6433985B2 publication Critical patent/JP6433985B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2016512111A 2013-05-03 2014-05-05 脳神経の耳麻酔により疾患を処置する方法 Active JP6433985B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361819023P 2013-05-03 2013-05-03
US61/819,023 2013-05-03
PCT/US2014/036855 WO2014179814A1 (en) 2013-05-03 2014-05-05 Method of treating disease by auricular anesthesia of cranial nerves

Publications (3)

Publication Number Publication Date
JP2016522819A JP2016522819A (ja) 2016-08-04
JP2016522819A5 JP2016522819A5 (enExample) 2017-06-08
JP6433985B2 true JP6433985B2 (ja) 2018-12-05

Family

ID=51844020

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016512111A Active JP6433985B2 (ja) 2013-05-03 2014-05-05 脳神経の耳麻酔により疾患を処置する方法
JP2018543020A Pending JP2018536709A (ja) 2013-05-03 2016-11-02 脳神経の耳麻酔による疾患の治療方法
JP2022016897A Active JP7512317B2 (ja) 2013-05-03 2022-02-07 脳神経の耳麻酔による疾患の治療方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018543020A Pending JP2018536709A (ja) 2013-05-03 2016-11-02 脳神経の耳麻酔による疾患の治療方法
JP2022016897A Active JP7512317B2 (ja) 2013-05-03 2022-02-07 脳神経の耳麻酔による疾患の治療方法

Country Status (17)

Country Link
US (4) US20140357686A1 (enExample)
EP (2) EP2991620B1 (enExample)
JP (3) JP6433985B2 (enExample)
KR (2) KR102086709B1 (enExample)
CN (2) CN105163718B (enExample)
AU (2) AU2014262148B2 (enExample)
CA (2) CA2910422C (enExample)
DK (1) DK2991620T3 (enExample)
ES (1) ES2823624T3 (enExample)
HK (1) HK1212230A1 (enExample)
IL (2) IL242339B (enExample)
MX (2) MX381106B (enExample)
MY (2) MY180310A (enExample)
RU (2) RU2687249C2 (enExample)
SG (1) SG11201508509XA (enExample)
WO (2) WO2014179814A1 (enExample)
ZA (2) ZA201508782B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2991620B1 (en) * 2013-05-03 2020-07-08 Crews, Thomas, M. Combinations of antipyrine and benzocaine for the treatment of diseases associated with a cranial nerve
WO2016137352A1 (ru) * 2015-02-26 2016-09-01 Общество С Ограниченной Ответственностью "Консорциум-Пик" Фармацевтическая композиция для лечения воспалительных заболеваний уха, способ ее получения и способ лечения указанной композицией
EP3509585B1 (en) 2016-09-07 2023-11-01 Glia, LLC Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves
US20220105052A1 (en) * 2016-12-26 2022-04-07 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
CN107789621A (zh) * 2017-12-15 2018-03-13 阜阳市平衡医疗保健器械有限公司 一种治疗头痛的药物及其配制方法
US11607275B2 (en) * 2019-05-20 2023-03-21 Medtronic Ireland Manufacturing Unlimited Company Selection of hypertensive patients for treatment with renal denervation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19524691A1 (de) * 1995-07-06 1997-01-09 Liedtke Pharmed Gmbh Methode und Zusammensetzung einer topischen Therapie von Innenohr und Labyrinth-Symptomen
RU2104056C1 (ru) * 1995-07-10 1998-02-10 Александр Александрович Ланцов Способ лечения периферических поражений лицевого нерва
JPH1094613A (ja) * 1996-08-02 1998-04-14 Mieko Sato 食欲調整用具
US6093417A (en) * 1999-01-11 2000-07-25 Advanced Medical Instruments Composition to treat ear disorders
ATE541565T1 (de) * 1999-05-27 2012-02-15 Khoury George F El Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus
DE10322497A1 (de) * 2003-05-19 2004-12-09 Liedtke, Rainer K., Dr. Topisch pharmakologische Vorbeugung und Therapie der Hyperakusis
US8940321B2 (en) * 2003-12-12 2015-01-27 Otic Pharma Ltd. Compositions for treatment of ear disorders and methods of use thereof
US8755892B2 (en) * 2007-05-16 2014-06-17 Cardiac Pacemakers, Inc. Systems for stimulating neural targets
US20110208161A1 (en) * 2009-08-13 2011-08-25 Yehuda Ivri Intracochlear drug delivery to the central nervous system
US20120252730A1 (en) * 2009-09-03 2012-10-04 University Of Chicago Platelet aggregation inhibitors
CA2848730A1 (en) * 2011-09-15 2013-03-21 Yoseph Yaacobi Systems and methods for treating ear disorders
EP2991620B1 (en) * 2013-05-03 2020-07-08 Crews, Thomas, M. Combinations of antipyrine and benzocaine for the treatment of diseases associated with a cranial nerve

Also Published As

Publication number Publication date
SG11201508509XA (en) 2015-11-27
MY180310A (en) 2020-11-28
US20180360745A1 (en) 2018-12-20
ZA201508782B (en) 2017-08-30
MX2015015194A (es) 2016-02-11
IL259019A (en) 2018-06-28
KR20180088408A (ko) 2018-08-03
JP7512317B2 (ja) 2024-07-08
JP2018536709A (ja) 2018-12-13
RU2015148757A (ru) 2017-06-08
EP2991620A1 (en) 2016-03-09
CA3004160A1 (en) 2017-05-11
EP2991620B1 (en) 2020-07-08
AU2016349784B2 (en) 2019-06-06
US9968589B2 (en) 2018-05-15
CN108430470A (zh) 2018-08-21
EP3370716A4 (en) 2019-04-17
US20140357686A1 (en) 2014-12-04
US20220387307A1 (en) 2022-12-08
CN105163718B (zh) 2020-03-17
MX2018005625A (es) 2018-12-06
BR112018008893A8 (pt) 2019-02-26
HK1212230A1 (en) 2016-06-10
CA3004160C (en) 2023-03-14
NZ713746A (en) 2021-01-29
AU2014262148B2 (en) 2018-11-22
NZ742076A (en) 2024-12-20
EP2991620A4 (en) 2017-01-11
US20160051516A1 (en) 2016-02-25
KR102086709B1 (ko) 2020-03-09
EP3370716A1 (en) 2018-09-12
RU2701548C1 (ru) 2019-09-30
JP2016522819A (ja) 2016-08-04
MY196979A (en) 2023-05-16
IL259019B (en) 2021-06-30
MX390998B (es) 2025-03-21
KR102796310B1 (ko) 2025-04-16
RU2687249C2 (ru) 2019-05-08
MX381106B (es) 2025-03-04
CA2910422A1 (en) 2014-11-06
IL242339B (en) 2020-05-31
AU2014262148A1 (en) 2015-11-05
BR112018008893A2 (pt) 2018-11-06
AU2016349784A1 (en) 2018-05-17
ES2823624T3 (es) 2021-05-07
CN105163718A (zh) 2015-12-16
DK2991620T3 (da) 2020-10-12
JP2022065015A (ja) 2022-04-26
WO2017079270A1 (en) 2017-05-11
CA2910422C (en) 2022-09-27
ZA201803483B (en) 2019-08-28
US11123284B2 (en) 2021-09-21
WO2014179814A1 (en) 2014-11-06
KR20160003012A (ko) 2016-01-08

Similar Documents

Publication Publication Date Title
JP6433985B2 (ja) 脳神経の耳麻酔により疾患を処置する方法
Kuchera et al. Osteopathic considerations in systemic dysfunction
US9821164B2 (en) Electrical treatment of bronchial constriction
Uchida et al. Novel mechanism of action hypothesized for stellate ganglion block related to melatonin
Loft et al. Hiccups: a case presentation and etiologic review
Hudson et al. A comparative historical and demographic study of the neuromodulation management techniques of deep brain stimulation for dystonia and cochlear implantation for sensorineural deafness in children
NZ713746B2 (en) Method of treating disease by auricular anesthesia of cranial nerves
CN103949010A (zh) 高频电流在治疗阻塞性睡眠呼吸暂停综合征的应用
BR112018008893B1 (pt) Composição farmacêutica óptica
Bhatnagar et al. Effects of bilateral thalamic stimulation on dichotic verbal processing
Dornhoffer et al. Pathophysiology of the Eustachian Tube: The Patulous Eustachian Tube
Klinkenberg et al. Vagus nerve stimulation in children with epilepsy a review of literature on efficacy, secondary effects, and side-effects
Wilma et al. Glomus Jugulare: A Case Series

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170421

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180501

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181009

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181107

R150 Certificate of patent or registration of utility model

Ref document number: 6433985

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250